Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0206 | 0.0206 |
Brugia malayi | RNA binding protein | 0.0259 | 0.7417 | 0.7417 |
Trichomonas vaginalis | penicillin-binding protein, putative | 0.0039 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0259 | 0.7417 | 0.7417 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 0.0206 | 0.0206 |
Trichomonas vaginalis | penicillin-binding protein, putative | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0259 | 0.7417 | 0.7417 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0206 | 0.0206 |
Plasmodium vivax | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Echinococcus granulosus | tumor protein p63 | 0.0332 | 0.9871 | 0.9871 |
Trichomonas vaginalis | esterase, putative | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0259 | 0.7417 | 0.7417 |
Mycobacterium ulcerans | lipase LipD | 0.0039 | 0 | 0.5 |
Echinococcus granulosus | high affinity choline transporter 1 | 0.0336 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0259 | 0.7417 | 0.7417 |
Echinococcus multilocularis | high affinity choline transporter 1 | 0.0336 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0045 | 0.0206 | 0.0206 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0259 | 0.7417 | 0.7417 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 0.0206 | 0.0206 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0129 | 0.3026 | 0.3026 |
Schistosoma mansoni | tar DNA-binding protein | 0.0259 | 0.7417 | 0.7417 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.0329 | 0.0329 |
Mycobacterium ulcerans | fusion of enoyl-CoA hydratase, EchA21 and lipase, LipE | 0.0039 | 0 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0129 | 0.3026 | 0.3026 |
Mycobacterium ulcerans | hypothetical protein | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | high-affinity choline transporter | 0.0336 | 1 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0259 | 0.7417 | 0.7417 |
Mycobacterium ulcerans | esterase/lipase LipP | 0.0039 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0259 | 0.7417 | 0.7417 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0336 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0259 | 0.7417 | 0.7417 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 0.0206 | 0.0206 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0259 | 0.7417 | 0.7417 |
Mycobacterium leprae | conserved hypothetical protein | 0.0039 | 0 | 0.5 |
Mycobacterium leprae | Probable lipase LipE | 0.0039 | 0 | 0.5 |
Brugia malayi | MH2 domain containing protein | 0.0129 | 0.3026 | 0.3026 |
Trichomonas vaginalis | D-aminoacylase, putative | 0.0039 | 0 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 0.0206 | 0.0206 |
Trichomonas vaginalis | D-aminoacylase, putative | 0.0039 | 0 | 0.5 |
Toxoplasma gondii | ABC1 family protein | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.0049 | 0.0329 | 0.0329 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0248 | 0.7041 | 1 |
Onchocerca volvulus | 0.0049 | 0.0329 | 1 | |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0045 | 0.0206 | 0.0206 |
Trichomonas vaginalis | D-aminoacylase, putative | 0.0039 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0259 | 0.7417 | 0.7417 |
Echinococcus multilocularis | tumor protein p63 | 0.0332 | 0.9871 | 0.9871 |
Mycobacterium ulcerans | beta-lactamase | 0.0039 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0039 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.0206 | 0.0206 |
Echinococcus granulosus | tar DNA binding protein | 0.0259 | 0.7417 | 0.7417 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 (functional) | > 100 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | > 100 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | > 3.7 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | > 3.7 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 6.08 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 6.08 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.